Concord Drugs has announced its unaudited financial results for the third quarter ended December 31, 2024. The company reported mixed performance metrics, reflecting challenges in its operations for the period.
Key Financial Highlights (in ₹):
- Revenue from Operations:
₹107.99 crore, down 12.63% from ₹123.60 crore in Q2 FY25, and a 15.53% decline YoY from ₹127.83 crore in Q3 FY24. - Total Expenses:
₹102.73 crore, a decrease of 16.53% QoQ from ₹123.05 crore but marginally lower than ₹130.40 crore in Q3 FY24. - Net Profit:
₹22.7 lakhs, up significantly from ₹4.4 lakhs in Q2 FY25 and a marked recovery from a loss of 24.1 lakhs in Q3 FY24.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
